Table 3 Incidence of major complications in different models of anticoagulant therapy in real world in patients with atrial fibrillation (AF)
Incidence of major complications (% pt-ys) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Author | Year | Drug | N | Mean age (years) | Total follow-up (pt-ys) | Mean follow-up (years) | Haemorrhagic | Thrombotic | Totalc | Mortality |
PSM of VKA | ||||||||||
Nagler [8] c | 2014 | VKA | 198 | 64.8 | 851a | 4.3a | 1.1 | 0.1 | 1.2a | 2.5 |
Grove [11] | 2018 | VKA | 534 | 63.1 | 1337 | 2.5 | 2.3 | 0.5 | 2.8 | 1.1 |
Our study | 2018 | VKA | 120 | 65.3 | 726 | 6.0 | 1.6 | 0.4 | 2.0 | 2.3 |
Conventional management of VKA in highly specialized centres | ||||||||||
Wieloch [23] | 2011 | VKA | 2491 | 74 | 2043 | 0.8a | 2.6 | 1.4 | 4.0 | NR |
Sjöegren [24] | 2015 | VKA | 51,229 | 72.1 | 143637a | 2.8a | 2.2 | 1.5 | 3.7 | NR |
Björck [25] | 2016 | VKA | 40,449 | 72.5 | 65,424 | 1.6a | 2.2 | 1.7 | 3.9 | 2.2 |
Esteve-Pastor [26] | 2018 | VKA | 1361 | 76 | 8844a | NR | 2.8 | 1.5 | 4.3a | 6.2 |
Conventional management of VKA | ||||||||||
Sorensen [27] | 2013 | VKA | 49,640 | 73.5 | 14892a | 0.3a | 4.3 | 0.7 | 5.0a | NR |
Lauffenburger [28] | 2015 | VKA | 43,865 | 71.4 | 43865a | 1.0 | 5.2a | 3.6a | 8.8a | NR |
Graham [29] | 2015 | VKA | 67,207 | 100% > 65 | 19,382 | 0.3a | 4.4 | 1.4 | 5.8a | 3.8 |
Seeger [30] | 2015 | VKA | 19,189 | 68.3 | 6448 | 0.3 | 6.2 | 1.3 | 7.4a | NR |
Larsen [31] | 2016 | VKA | 35,436 | 72.4 | 67328a | 1.9 | 3.5 | 2.4 | 5.9a | 7.2 |
Carmo [32]b | 2016 | VKA | 501,019 | NR | NR | NR | 5.6 | 2.8 | 8.4a | 6.1 |
Nielsen [33] | 2017 | VKA | 38,893 | 71.0 | 89453a | 2.3 | 3.1 | 2.7 | 5.8a | 8.7 |
Chan [34] | 2016 | VKA | 5251 | 71 | 4726a | 0.9a | 4.3 | 5.6 | 9.9 | 7.1 |
Li [35] | 2017 | VKA | 38,470 | 70.9 | NR | NR | 7.5 | 3.1 | 10.6a | NR |
Mentias [36] | 2018 | VKA | 101,705 | 78.4 | NR | NR | 5.3 | 2.1 | 7.4a | 6.7 |
Lee [37] | 2018 | VKA | 12,183 | 70.7 | 10,965 | 0.9 | 3.6 | 3.9 | 7.5a | 6.6 |
Gupta [38] | 2018 | VKA | 7607 | 76.6 | 5051a | NR | 4.7 | 1.9 | 6.6a | NR |
Vinogradova [39] | 2018 | VKA | 53,921 | 74.8 | 73,939 | NR | 2.5 | 1.7 | 4.2a | 4.5 |
Chan [40] | 2018 | VKA | 19,375 | 71.0 | 28481a | 1.47 | 3.0 | 3.3 | 6.3a | 9.1 |
DOACs | ||||||||||
Graham [29] | 2015 | Dabigatran | 67,207 | 100% > 65 | 18,205 | 0.3a | 4.3 | 1.1 | 5.4a | 3.3 |
Lauffenburger [28] | 2015 | Dabigatran | 21,070 | 67.5 | 21070a | 1.0 | 3.2 | 1.7 | 4.9a | NR |
Seeger [30] | 2015 | Dabigatran | 19,189 | 68.7 | 8059 | 0.4 | 4.4 | 1.0 | 5.4a | NR |
Larsen [31] | 2016 | Dabigatran | 12,701 | 67.6 | 24131a | 1.9a | 2.0 | 1.8 | 3.8a | 2.4 |
Graham [41] | 2016 | Dabigatran | 52,240 | 100% > 65 | 15,524 | 0.3a | 3.1 | 1.0 | 4.1a | 2.2 |
Carmo [32]b | 2016 | Dabigatran | 210,279 | NR | NR | NR | 3.9 | 1.6 | 5.5a | 3.6 |
Chan [34] | 2016 | Dabigatran | 5921 | 75 | 5329a | 0.9a | 2.6 | 3.7 | 6.3a | 2.6 |
Nielsen [33] | 2017 | Dabigatran | 8875 | 79.9 | 20,412 | 2.3 | 2.8 | 2.7 | 5.5a | 9.1 |
Mentias [36] | 2018 | Dabigatran | 21,979 | 75.8 | NR | NR | 3.4 | 1.5 | 4.9a | 2.6 |
Gupta [38] | 2018 | Dabigatran | 4129 | 73.0 | 3061a | NR | 3.6 | 1.0 | 4.6a | NR |
Vinogradova [39] | 2018 | Dabigatran | 4534 | 74.7 | 5083 | NR | 2.2 | 1.7 | 3.9a | 4.3 |
Chan [40] | 2018 | Dabigatran | 20,079 | 75.0 | 31122a | 1.55 | 2.0 | 2.7 | 4.7a | 5.0 |
Laliberté [42] | 2014 | Rivaroxaban | 3654 | 73.3 | 831a | 0.23 | 3.3 | 4.6 | 7.9a | NR |
Camm [43] | 2016 | Rivaroxaban | 6784 | 71.5 | 6196a | 0.9 | 2.1 | 0.8 | 2.9a | 1.9 |
Larsen [31] | 2016 | Rivaroxaban | 7192 | 71.8 | 13664a | 1.9a | 3.6 | 2.3 | 5.9a | 6.7 |
Graham [41] | 2016 | Rivaroxaban | 66,651 | 100% > 65 | 20,199 | 0.3a | 4.5 | 0.8 | 5.3a | 2.5 |
Chan [34] | 2016 | Rivaroxaban | 3916 | 76 | 3524a | 0.9a | 3.4 | 3.1 | 6.5a | 3.3 |
Nielsen [33] | 2017 | Rivaroxaban | 3476 | 77.9 | 7994a | 2.3 | 4.0 | 2.7 | 6.7a | 13.5 |
Mentias [36] | 2018 | Rivaroxaban | 23,177 | 75.7 | NR | NR | 4.7 | 1.4 | 6.1a | 3.1 |
Gupta [38] | 2018 | Rivaroxaban | 11,284 | 75.3 | 8303a | NR | 4.4 | 1.3 | 5.7a | NR |
Vinogradova [39] | 2018 | Rivaroxaban | 13,597 | 75.8 | 12,679 | NR | 2.6 | 1.6 | 4.2a | 5.5 |
Chan [40] | 2018 | Rivaroxaban | 27,777 | 75.0 | 34443a | 1.24 | 2.1 | 2.8 | 4.9a | 6.0 |
Larsen [31] | 2016 | Apixaban | 6349 | 71.3 | 5714 | 0.9 | 2.7 | 4.1 | 6.8 | 4.8 |
Nielsen [33] | 2017 | Apixaban | 4400 | 83.9 | 4400a | 1.0 | 3.9 | 4.0 | 7.9a | 14.8 |
Li [35] | 2017 | Apixaban | 38,470 | 70.9 | NR | NR | 4.5 | 2.1 | 6.6a | NR |
Gupta [38] | 2018 | Apixaban | 11,284 | 75.3 | 7000a | NR | 2.9 | 1.0 | 3.9a | NR |
Vinogradova [39] | 2018 | Apixaban | 9199 | 76.5 | 7511 | NR | 1.5 | 1.8 | 3.3a | 5.3 |
Chan [40] | 2018 | Apixaban | 5843 | 76.0 | 4440a | 0.76 | 1.5 | 2.3 | 3.8a | 7.2 |
Lee [37] | 2018 | Edoxaban | 4061 | 70.3 | 1218 | 0.3 | 2.3 | 3.2 | 5.5a | 5.6 |
Grove [11] | 2018 | All | 2671 | 63.6 | 5075 | 1.9a | 2.3 | 1.6 | 3.9a | 1.4 |